ClinicalTrials.gg
CompletedNCT00841568Updated Sep 11, 2018Results posted

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

A Phase 2 interventional study of OPC-41061 in Autosomal Dominant Polycystic Kidney Disease, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Per ClinicalTrials.gov, last updated 2018-09-11.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.

Enrollment
17th of 18
17 · median 91
Started
2006
the only one that year
Phase 2
7 of 18
none open now
Registered
3rd of 18
by date
Lead sponsor
3 of 18
Otsuka Pharmaceutical Co., Ltd.

Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 17th largest by enrollment, is the only one that started in 2006, is one of 7 in phase 2, and was the 3rd registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant as a file.
02

Study summary

Investigation into the long-term safety and efficacy of OPC-41061 in repeated oral administrations at doses of 15 mg twice daily in patients with ADPKD who completed the preceding dose-finding study (156-04-001).

Read the detailed description

Investigation into the long-term safety and efficacy of OPC-41061 in repeated oral administrations at doses of 15 mg twice daily in patients with ADPKD who completed the preceding dose-finding study (156-04-001).

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease

Keywords

  • ADPKD
  • Tolvaptan
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed 5-day repeated administrations and the follow-up observation in the preceding study (156-04-001)
  • Patients in whom the safety of repeated administration was confirmed based on the investigator's reports from the preceding study (156-04-001)

Exclusion criteria

Exclusion Criteria:

  • Patients with serum creatinine concentration of 2.5 mg/dL or higher at the screening examination
  • Patients with any of the following complications

    • Uncontrolled hypertension
    • Serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)"
  • Patients with any of the following complications or history thereof

    • drug allergies (anaphylaxis) or (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity thereto)
    • Inability to personally give consent due to a mental disease "
  • Patients with SBP (in sitting position) \<90 mm Hg (at screening examination)
  • Patients with history of massive bleeding or bleeding tendency
  • Patients with a history of drug or alcohol abuse within 6 months prior to the screening examination
  • Pregnant women, lactating women, or women who may become or plan to become pregnant
  • Patients who received any drug other than OPC-41061 within 30 days prior to commencement of administration of OPC-41061
  • Any patient who, in the opinion of the principle investigator or attending investigators, should not participate in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    1

    Drug: OPC-41061

Interventions

  • orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.

06

What researchers measure

Primary outcomes

  1. Total Kidney Volume

    Individual subject data on the volumes of the total kidney volume (sum of the volumes of the left and right kidneys) measured by magnetic resonance imaging or computed tomography during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

    Time frame: Baseline, week 24, 52, 104, and 156

  2. Renal Function Test (eGFR)

    Individual subject data on eGFR (estimated glomerular filtration rate calculated by Japanese eGFR equation) during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

    Time frame: Baseline, Week 24, 48, 104, and 156

07

Results

Posted Jul 27, 2018

Participant flow

Participant flow — Overall Study
MilestoneOPC-41061
Started17
Completed12
Not completed5
Withdrew: Adverse event1
Withdrew: Death1
Withdrew: Withdrawal by subject2
Withdrew: Creatinine over the withdrawal criteria1

Outcome measures

PrimaryTotal Kidney Volume

Individual subject data on the volumes of the total kidney volume (sum of the volumes of the left and right kidneys) measured by magnetic resonance imaging or computed tomography during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

Time frame:
Baseline, week 24, 52, 104, and 156
Reported as:
Median · mL
Total Kidney Volume
mLBaselineWeek 24Week 52Week 104Week 156
Total Kidney Volume1500.5 (781.5 to 5060.1)1573.1 (770.0 to 5036.6)1567.9 (774.2 to 4940.3)1729.4 (858.4 to 4869.0)1647.7 (868.0 to 2563.8)
PrimaryRenal Function Test (eGFR)

Individual subject data on eGFR (estimated glomerular filtration rate calculated by Japanese eGFR equation) during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

Time frame:
Baseline, Week 24, 48, 104, and 156
Reported as:
Median · mL/min/1.73m2
Renal Function Test (eGFR)
mL/min/1.73m2BaselineWeek 24Week 52Week 104Week 156
Renal Function Test (eGFR)63.0 (33 to 108)64.0 (29 to 115)64.0 (35 to 122)58.5 (35 to 114)59.0 (27 to 103)

Adverse events

Collected over 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPC-410611/17 (5.9%)2/17 (11.8%)17/17 (100%)
Most frequent serious events
Most frequent serious events
EventOPC-41061
DiverticulitisInfections and infestations1/17
Subarachnoid haemorrhageNervous system disorders1/17
Most frequent other events
Showing 10 of 128
Most frequent other events
EventOPC-41061
NasopharyngitisInfections and infestations13/17
ThirstGeneral disorders9/17
ContusionInjury, poisoning and procedural complications6/17
Blood antidiuretic hormone increasedInvestigations5/17
HypertensionVascular disorders5/17
Blood uric acid increasedInvestigations4/17
HeadacheNervous system disorders4/17
PalpitationsCardiac disorders3/17
VertigoEar and labyrinth disorders3/17
Dental cariesGastrointestinal disorders3/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)OPC-41061
<=18 years0
Between 18 and 65 years17
>=65 years0
Age, Continuous
Age, Continuous(years)OPC-41061
Mean41.8 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)OPC-41061
Female9
Male8
Region of Enrollment
Region of Enrollment(participants)OPC-41061
Japan17
08

Study locations

1 site
  • Kanto Region, Japan
09

References and documents

Publications

  • Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS; TEMPOFormula and 156-05-002 Study Investigators. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507. doi: 10.2215/CJN.03530411. Epub 2011 Sep 8. PubMed 21903984 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2018, 7 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2009
First posted
Feb 11, 2009
Start
Apr 2006
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Jul 27, 2018
Last update
Sep 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00841568
First posted
Feb 11, 2009
Start date
Apr 2006
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Jul 27, 2018
Last update
Sep 11, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion